Q2 2025 Bactiguard Holding AB Earnings Call Transcript
Key Points
- Bactiguard Holding AB (OSTO:BACTI B) achieved its fifth consecutive quarter of positive EBITDA, totaling SEK4.4 million.
- The company reported a 21% growth in its wound management portfolio over the first six months of 2025, driven by the Hydrocyn Aqua brand.
- Bactiguard's collaboration with BD remains strong, with new market registrations underway, including successful registration in India.
- The company is expanding its strategic focus into cardiology, with early feasibility work initiated under a material transfer agreement.
- Bactiguard is enhancing its capabilities in business development, R&D, and regulatory areas to strengthen partnerships and drive growth.
- Total revenues for Q2 2025 decreased by 14.4% to SEK52.1 million, impacted by lower revenues from the BD partnership and negative currency effects.
- The BD partnership experienced delays in new market registrations, affecting revenue timelines.
- Revenues from the wound management portfolio were slightly lower compared to Q2 last year due to slower sales of suture products.
- The company reported an operating loss of SEK7.3 million for Q2, although this was an improvement from the previous year.
- Bactiguard's commercialization efforts in Europe are facing delays due to longer-than-expected timelines for CE mark approvals.
Thank you, operator, and welcome to the presentation of Bactiguard's report for the second quarter 2025. Our CFO, Patrick Bach, and I will go through the presentation together and we will have a Q&A session towards the end.
As usual, I would like to share some highlights from the past quarter, and Patrick will go through the figures in more detail later in the presentation.
First, we continue to deliver EBITDA profitability with this quarter totaling SEK4.4 million. This is the fifth consecutive quarter with positive EBITDA for Bactiguard in alignment with our promise to our investors during our strategic transformation. Revenues for Q2 came in at SEK52.1 million, which was a decrease of 14.4% compared to last year. This is mainly explained by lower revenues from the BD partnership due to longer than expected timelines for new market registrations, as well as negative US dollar currency impact.
Nevertheless, our collaboration with BD remains solid, and I will elaborate on this later in the presentation. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
